cotinine fumarate

Small moleculeexperimental

Cotinine is an alkaloid found in tobacco and is also the predominant metabolite of nicotine, typically used as a biomarker for exposure to tobacco smoke. Cotinine is currently being studied as a treatment for depression, post-traumatic stress disorder (PTSD), schizophrenia, Alzheimer's disease and Parkinson's disease. Cotinine was developed as an antidepressant as a fumaric acid salt, cotinine fumarate, to be sold under the brand name Scotine, but it was never marketed. — Wikipedia

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 1995 (NCT00000284)

Timeline

1990s

Jan 1, 1995
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Tobacco Use Disorder · Phase 2

Mechanism of action

Neuronal nicotinic acetylcholine receptorACTIVATOR
Neuronal nicotinic acetylcholine receptor activator

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(=O)CC[C@H]1c1cccnc1.CN1C(=O)CC[C@H]1c1cccnc1.O=C(O)/C=C/C(=O)O

Mol. weight: 468.51 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

cotinine fumarate
cotinine fumarate
cotinine fumarate

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00000296	Phase 2	Nov 1, 1997	National Institute on Drug Abuse (NIDA), University of Minnesota
NCT00000288	Phase 2	Dec 1, 1995	National Institute on Drug Abuse (NIDA), University of Minnesota
NCT00000284	Phase 2	Feb 1, 1995	National Institute on Drug Abuse (NIDA), University of Minnesota

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Institute on Drug Abuse (NIDA)	Government	3	3	1	1995
University of Minnesota	Academic/Hospital	3	0	1	1995

2 organizations

Page 1 / 1